Yijia Group CORP

VitaNova Life Sciences Corporation announced the appointment of its Chief Financial Officer, Steve Niu, to its Board of Directors, effective February 19, 2026.

VitaNova Life Sciences Corporation announced the completion of its name change, 1-for-3 reverse stock split, and upcoming ticker symbol change to VNOV, effective for trading on the OTC Pink marketplace.

Yijia Group Corp. announced a corporate rebranding to VitaNova Life Sciences Corporation, a 1-for-3 reverse stock split, and the designation of Series A Preferred Stock.

Yijia Group Corp. announced plans for a corporate name change to VitaNova Life Sciences Corporation, a reverse stock split, and an increase in authorized capital, all approved by its Board and shareholders.

Yijia Group Corp. has replaced its independent registered public accounting firm, Olayinka Oyebola & Co., with Simon & Edward, LLP, effective June 5, 2024.

Yijia Group Corp. successfully completed a private offering of its common stock, raising $957,051 from ten investors.

VitaNova Life Sciences Corp. reported a net loss for Q3 and the nine months ended January 31, 2026, despite significant revenue growth driven by its dietary supplement segment, primarily due to increased general and administrative expenses and cost of revenue.

Yijia Group Corp. reported a significant increase in revenue and gross profit for the three and six months ended October 31, 2025, driven by its dietary supplement segment, despite identifying material weaknesses in internal controls.

Yijia Group Corp. reported a net loss of $46,301 for the quarter ended July 31, 2025, a slight improvement from the prior year, despite a 4% decrease in total revenue.

Yijia Group Corp. reports a substantial revenue increase in Q3 2025, primarily driven by the commencement of its healthcare products segment.

Yijia Group Corp. reports its first revenue from healthcare products and consulting services in its 10-Q filing for the period ended October 31, 2024, while also disclosing material weaknesses in internal controls.

Yijia Group Corp. reports its first revenue of $108,477 in the first quarter of 2025, primarily from healthcare product sales, but still experiences a net loss of $55,211.

VitaNova Life Sciences Corporation's annual report for fiscal year 2026 shows a 14% increase in revenue to $3.03 million, driven by its new healthy food products line, though net income turned to a loss of $37,304.

Yijia Group Corp. announced significantly increased revenues and net income for fiscal year 2025, primarily fueled by the rapid expansion of its healthcare products segment, despite ongoing internal control deficiencies.

Yijia Group Corp. experienced a substantial increase in revenue during fiscal year 2024, primarily due to the expansion of its healthcare product sales.